{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T23:03:31Z","timestamp":1773702211528,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019125","name":"National Institute of Pharmaceutical Education and Research, Ahmedabad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019125","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100025010","name":"Dipartimento di Scienze del Farmaco, Universit\u00e0 degli Studi di Padova","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100025010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ejphar.2025.178067","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T06:37:15Z","timestamp":1755153435000},"page":"178067","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Empagliflozin attenuates liver steatosis and improves cardiac complications in choline-deficient high-fat diet-induced MAFLD rats"],"prefix":"10.1016","volume":"1005","author":[{"given":"Navya","family":"Malladi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditi D.","family":"Hase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudheer","family":"Arava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajni","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jagdish Kumar","family":"Balani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4500-6070","authenticated-orcid":false,"given":"Anurag","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0008-0480","authenticated-orcid":false,"given":"Sanjay K.","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.178067_bib1","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.3390\/ijms23063107","article-title":"SGLT-2 inhibitors in NAFLD: expanding their role beyond diabetes and cardioprotection","volume":"23","author":"Androutsakos","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.178067_bib2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev-pathol-020117-043617","article-title":"Recent insights into the pathogenesis of nonalcoholic Fatty liver disease","volume":"13","author":"Arab","year":"2018","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.ejphar.2025.178067_bib3","doi-asserted-by":"crossref","first-page":"H932","DOI":"10.1152\/ajpheart.00668.2016","article-title":"Noninvasive stratification of postinfarction rats based on the degree of cardiac dysfunction using magnetic resonance imaging and echocardiography","volume":"312","author":"Aronsen","year":"2017","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ejphar.2025.178067_bib4","doi-asserted-by":"crossref","first-page":"715","DOI":"10.4254\/wjh.v9.i16.715","article-title":"Non-alcoholic fatty liver disease: an expanded review","volume":"9","author":"Benedict","year":"2017","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.ejphar.2025.178067_bib5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2478\/rjdnmd-2019-0005","article-title":"Oral supplementation effect of iron and its complex form with Quercetin on oxidant status and on redistribution of essential metals in organs of Streptozotocin diabetic rats","volume":"26","author":"Berroukeche","year":"2019","journal-title":"Romanian J. Diabetes Nutr. Metab. Dis."},{"key":"10.1016\/j.ejphar.2025.178067_bib6","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/0002-9149(78)90723-3","article-title":"Significance of changes in R wave amplitude during treadmill stress testing: angiographic correlation","volume":"41","author":"Bonoris","year":"1978","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ejphar.2025.178067_bib7","series-title":"Statpearls","article-title":"Left ventricular hypertrophy","author":"Bornstein","year":"2023"},{"key":"10.1016\/j.ejphar.2025.178067_bib8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00125-019-05024-3","article-title":"Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality","volume":"63","author":"Brouwers","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2025.178067_bib9","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7570\/jomes23052","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): a state-of-the-art review","volume":"32","author":"Chan","year":"2023","journal-title":"J. Obes. Metab. Syndr."},{"key":"10.1016\/j.ejphar.2025.178067_bib10","first-page":"2445","article-title":"The association of non-alcoholic fatty liver disease and cardiac structure and function \u2013 Framingham heart study","volume":"40","author":"Chiu","year":"2020","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"},{"key":"10.1016\/j.ejphar.2025.178067_bib11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/03602532.2017.1293683","article-title":"Non-Alcoholic Fatty Liver Disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters","volume":"49","author":"Cobbina","year":"2017","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.ejphar.2025.178067_bib12","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12876-023-02708-4","article-title":"Correlation between nonalcoholic fatty liver disease and left ventricular diastolic dysfunction in non-obese adults: a cross-sectional study","volume":"23","author":"Cong","year":"2023","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.ejphar.2025.178067_bib13","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.amjcard.2016.12.011","article-title":"Influence of left ventricular stroke volume on incident heart failure in a population with preserved ejection fraction (from the strong heart study)","volume":"119","author":"De Marco","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ejphar.2025.178067_bib14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13098-017-0238-9","article-title":"Association of metabolic syndrome and electrocardiographic markers of subclinical cardiovascular disease","volume":"9","author":"Elffers","year":"2017","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.ejphar.2025.178067_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-29639-5","article-title":"Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis","volume":"8","author":"Fadaei","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2025.178067_bib17","series-title":"Manual of Exercise Testing","first-page":"1","article-title":"Chapter 1 - the physiologic response to the exercise test","author":"Froelicher","year":"2007"},{"key":"10.1016\/j.ejphar.2025.178067_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.metop.2020.100039","article-title":"Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis","volume":"7","author":"Garg","year":"2020","journal-title":"Metab. Open"},{"key":"10.1016\/j.ejphar.2025.178067_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222212408","article-title":"Empagliflozin ameliorates free fatty acid induced-lipotoxicity in renal proximal tubular cells via the PPAR\u03b3\/CD36 pathway in Obese mice","volume":"22","author":"Huang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.178067_bib20","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1210\/clinem\/dgaa321","article-title":"Cardiovascular benefit of empagliflozin across the spectrum of cardiovascular risk factor control in the EMPA-REG OUTCOME trial","volume":"105","author":"Inzucchi","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2025.178067_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003100","article-title":"Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of population-based observational studies","volume":"17","author":"Jarvis","year":"2020","journal-title":"PLoS Med."},{"key":"10.1016\/j.ejphar.2025.178067_bib22","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3390\/cells9020451","article-title":"The crosstalk between cardiac lipotoxicity and mitochondrial oxidative stress in the cardiac alterations in diet-induced obesity in rats","volume":"9","author":"Jim\u00e9nez-Gonz\u00e1lez","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2025.178067_bib23","first-page":"155","article-title":"Differential diagnosis of wide QRS tachycardias. Arrhythmia electrophysiol","volume":"9","author":"Katritsis","year":"2020","journal-title":"Rev"},{"key":"10.1016\/j.ejphar.2025.178067_bib24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.5582\/ddt.2017.01069","article-title":"Long-term use of ipragliflozin improved cardiac sympathetic nerve activity in a patient with heart failure: a case report","volume":"12","author":"Kiuchi","year":"2018","journal-title":"Drug Discov. Ther."},{"key":"10.1016\/j.ejphar.2025.178067_bib25","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.3390\/ijms23084195","article-title":"Remodeling and fibrosis of the cardiac muscle in the course of obesity\u2014pathogenesis and involvement of the extracellular matrix","volume":"23","author":"Kruszewska","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.178067_bib26","first-page":"2809","article-title":"2019 global NAFLD prevalence: a systematic review and meta-analysis","volume":"20","author":"Le","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"key":"10.1016\/j.ejphar.2025.178067_bib27","doi-asserted-by":"crossref","first-page":"8407","DOI":"10.3748\/wjg.v20.i26.8407","article-title":"Nonalcoholic fatty liver disease and cardiovascular disease","volume":"20","author":"Liu","year":"2014","journal-title":"World J. Gastroenterol. WJG"},{"key":"10.1016\/j.ejphar.2025.178067_bib28","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/s12944-018-0898-y","article-title":"Effect of serum triglyceride level on the prognosis of patients with hepatocellular carcinoma in the absence of cirrhosis","volume":"17","author":"Liu","year":"2018","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.ejphar.2025.178067_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2024.111299","article-title":"Paricalcitol attenuates oxidative stress and inflammatory response in the liver of NAFLD rats by regulating FOXO3a and NF\u03baB acetylation","volume":"121","author":"Malladi","year":"2024","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ejphar.2025.178067_bib30","first-page":"134","article-title":"Nonalcoholic fatty liver disease (NAFLD) and risk of cardiac arrhythmias: a new aspect of the liver-heart axis","volume":"5","author":"Mantovani","year":"2017","journal-title":"J. Clin. Transl. Hepatol."},{"key":"10.1016\/j.ejphar.2025.178067_bib31","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1590-8658(02)80111-6","article-title":"Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild\/moderate abnormalities of liver transaminases","volume":"34","author":"Mathiesen","year":"2002","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.ejphar.2025.178067_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1393946","article-title":"Empagliflozin alters lipid metabolism in the myocardium and liver in a prediabetes model with severe dyslipidemia","volume":"15","author":"Miklankova","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178067_bib33","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ahj.2024.08.021","article-title":"Contributors to high left ventricular ejection fraction in women with ischemia and no obstructive coronary artery disease: results from the Women's Ischemia Syndrome Evaluation\u2014Coronary Vascular Dysfunction (WISE-CVD) Study","volume":"278","author":"Nelson","year":"2024","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ejphar.2025.178067_bib34","series-title":"Statpearls","article-title":"Wide QRS complex tachycardia","author":"Obando","year":"2025"},{"key":"10.1016\/j.ejphar.2025.178067_bib35","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1161\/01.HYP.0000125230.46080.c6","article-title":"QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy","volume":"43","author":"Oikarinen","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2025.178067_bib36","series-title":"Statpearls","article-title":"Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors","author":"Padda","year":"2025"},{"key":"10.1016\/j.ejphar.2025.178067_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s43440-019-00020-1","article-title":"New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis","volume":"72","author":"Pydyn","year":"2020","journal-title":"Pharmacol. Rep. PR"},{"key":"10.1016\/j.ejphar.2025.178067_bib38","article-title":"The significance of reporting increased liver echogenicity in nonalcoholic fatty liver patients","volume":"11","author":"Qudsieh","year":"2022","journal-title":"Ann. Med. Health Sci. Res."},{"key":"10.1016\/j.ejphar.2025.178067_bib39","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-020-01127-z","article-title":"Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial","volume":"19","author":"Shimizu","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ejphar.2025.178067_bib40","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1136\/gutjnl-2021-325724","article-title":"Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort","volume":"71","author":"Simon","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.ejphar.2025.178067_bib41","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.3748\/wjg.v21.i14.4103","article-title":"Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question","volume":"21","author":"Streba","year":"2015","journal-title":"World J. Gastroenterol. WJG"},{"key":"10.1016\/j.ejphar.2025.178067_bib42","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.3390\/ijerph16173104","article-title":"Cardiovascular risk in non-alcoholic fatty liver disease: mechanisms and therapeutic implications","volume":"16","author":"Tana","year":"2019","journal-title":"Int. J. Environ. Res. Publ. Health"},{"key":"10.1016\/j.ejphar.2025.178067_bib43","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications","volume":"69","author":"Targher","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.ejphar.2025.178067_bib44","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3892\/br.2014.309","article-title":"Triglyceride is strongly associated with nonalcoholic fatty liver disease among markers of hyperlipidemia and diabetes","volume":"2","author":"Tomizawa","year":"2014","journal-title":"Biomed. Rep"},{"key":"10.1016\/j.ejphar.2025.178067_bib45","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1016\/j.jacc.2023.04.034","article-title":"Effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations","volume":"81","author":"Usman","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2025.178067_bib46","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014279","article-title":"Longitudinal association of non\u2010alcoholic fatty liver disease with changes in myocardial structure and function: the CARDIA study","volume":"9","author":"VanWagner","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ejphar.2025.178067_bib47","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jacbts.2018.07.006","article-title":"Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors","volume":"3","author":"Verma","year":"2018","journal-title":"JACC Basic Transl. Sci."},{"key":"10.1016\/j.ejphar.2025.178067_bib48","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3389\/fendo.2020.00179","article-title":"Higher serum uric acid level predicts non-alcoholic fatty liver disease: a 4-Year prospective cohort study","volume":"11","author":"Wei","year":"2020","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejphar.2025.178067_bib49","article-title":"Elevated ALT\/AST ratio as a marker for NAFLD risk and severity: insights from a cross-sectional analysis in the United States","volume":"15","author":"Xuan","year":"2024","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejphar.2025.178067_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0091436","article-title":"Evaluation of dietary effects on hepatic lipids in high fat and placebo diet fed rats by in vivo MRS and LC-MS techniques","volume":"9","author":"Yaligar","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2025.178067_bib51","article-title":"Efficacy and safety of empagliflozin on nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Endocrinol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925008210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925008210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T14:01:32Z","timestamp":1772805692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925008210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":50,"alternative-id":["S0014299925008210"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178067","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Empagliflozin attenuates liver steatosis and improves cardiac complications in choline-deficient high-fat diet-induced MAFLD rats","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"178067"}}